Program
CS-121
A development code.
Its studies are mostly in Hypertriglyceridemia, led by CorrectSequence Therapeutics.
Furthest: early phase 1, since Aug 30, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2026 (early phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CorrectSequence Therapeutics | 22 open or running | early phase 1since Aug 30, 2025 | Aug 30, 2025 | Dec 2026early phase 1 · NCT07176923 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 30, 2025First study: early phase 1 study in Familial hyperchylomicronemia syndromeFirst studyNCT07176923 · 15 planned · China
- Jun 15, 2026Early phase 1 study in HypertriglyceridemiaNCT07657780 · 15 planned · China
Ahead
- Dec 2026Primary completion: early phase 1 study in Familial hyperchylomicronemia syndromeNCT07176923
- Mar 15, 2028Primary completion: early phase 1 study in HypertriglyceridemiaNCT07657780
TargetBeta
APOC3 →read by rule
“A Clinical Study to the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of CS-121, an In Vivo Base Editing Therapy Delivered by Lipid Nanoparticles Targeting APOC3 for the Treatment of Severe Hypertriglyceridemia in Adults”study text, by rule · the study
Other programs on APOC3
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07657780Hypertriglyceridemia · China | Early 1 | Not yet recruiting | Mar 15, 2028 | 15 |
| NCT07176923Familial hyperchylomicronemia syndrome · China | Early 1 | Recruiting | Dec 2026 | 15 |
How it is read
Names in the registry
- “CS-121”, 2 entries
Codes read as this program: CS121.
Conditions, from the studies’ own filings
- Hypertriglyceridemia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.